Ventus Treatments announced successful completion stage 1 Clinical trial initiation is planned for VENT-03 stage 2 work for people with systemic lupus erythematosus (SLE) In 2025.

VENT-03, the first drug of its kind to enter clinical development, is an oral therapy designed to target and block cGAS, a cell receptor associated with lupus and a wide range of other cells. autoimmune diseases. Pharmacokinetics, target interaction, safety and tolerability in 72 healthy adult volunteers. The results showed that VENT-03 was safe and well tolerated at all dose levels tested, and all treatment-related side effects were mild and easily managed. VENT-03 demonstrated a favorable pharmacokinetic profile favoring once-daily dosing. Additionally, VENT-03 reached plasma concentrations required for complete target inhibition and demonstrated potent pharmacodynamic (what a drug does to the body) effects.

Stay tuned to the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about drugs used to treat lupus.

Read the announcement